Case series of 83 XDR-TB patients in an urban hospital of Gujarat, India; an interim analysis Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes Year: 2015
Fifteen years period (2000-2014) of resistant TB forms in Vojvodina (Serbia) Source: International Congress 2015 – Management of TB: a patient focus Year: 2015
Prevalence of drug resistance in Italy: national report, year 2000 Source: Eur Respir J 2002; 20: Suppl. 38, 402s Year: 2002
Adverse drug reactions to second line anti tuberculosis drugs: A prospective study in Mumbai, India Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013
Outcomes of MDR cases in Iasi county, Romania Source: Annual Congress 2005 - Resistant and multidrug resistant tuberculosis Year: 2005
Impact of pre-treatment duration by first line drugs on treatment outcomes of patients with MDR-TB Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015
Number of tuberculosis (TB) cases reported by primary care physicians (PCPs) in India: Results of a 1-day point prevalence study in 880 urban cities and towns in India Source: Annual Congress 2013 –Tuberculosis: epidemiology and public health management I Year: 2013
Particularities of a cohort of preXDR / XDR TB patients treated with group 5 medication, hospitalized in MDR TB Department Institute of Pneumophtisiology Bucharest, Romania Source: International Congress 2016 – Update on drug-resistant tuberculosis Year: 2016
Pattern of second line drug-resistance in MDR-TB treatment failure cases at a tertiary care tuberculosis treatment centre in western region of India Source: International Congress 2016 – Update on drug-resistant tuberculosis Year: 2016
Treatment outcomes and deaths among multidrug-resistant tuberculosis (MDR-TB) patients in Gomel region, Belarus – 2009-2010 Source: Annual Congress 2013 –Drug-resistant tuberculosis: new clinical and public health insights Year: 2013
Study of prevalence of drug resistance in tuberculosis (TB) patients attending a tertiary care hospital at Mumbai Source: International Congress 2016 – Epidemiological insights into tuberculosis pathogenesis Year: 2016
Practicing empirical anti-tuberculosis treatment (ATT) in suspected spinal tuberculosis (STB): Follow up of 33 cases from Sri Lanka, a limited resource setting with an intermediate disease burden Source: Annual Congress 2011 - Extrapulmonary tuberculosis and surgical interventions Year: 2011
Treatment outcome among HIV positive and HIV negative TB patients in Chandigarh, India: A retrospective cohort study Source: International Congress 2015 – Management of TB: a patient focus Year: 2015
Trend of acquired drug resistance to main anti TB drugs in the first 7 years of applying DOT strategy in Iasi County, Romania Source: Annual Congress 2007 - Tuberculosis control Year: 2007
Four cases, one family: A cluster of resistant tuberculosis Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013
A comparison of drug sensitivity pattern in category-I failure versus category-I relapse pulmonary TB patients attending a tertiary care hospital in South Punjab, Pakistan. Is WHO category-II ATT regimen appropriate? Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013
Patients over 35 years experience more side-effects during latent TB treatment: Experience from an urban hospital with a high incidence of Tuberculosis Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes Year: 2015
A two-year post-treatment follow-up of multi-drug resistant tuberculosis cases who completed a programmatic MDR-TB management at the lung center of the Philippines – a preliminary report Source: Annual Congress 2009 - Multi/extensively-drug resistant tuberculosis Year: 2009
The management of MDR TB cases registered in the 4th sector of Bucharest during 2004-2006 Source: Annual Congress 2010 - Emerging drug resistance in tuberculosis Year: 2010
Experience of managing TB/HIV infection in a regional UK center over a 5 year period Source: International Congress 2016 – Non-tuberculous mycobacteria: HIV-TB co-infection and adenosine deaminase (ADA) Year: 2016